Patients With COVID-19 Treated With Molnupiravir Reported Less Time Off From Work Or Study, And Less Healthcare Utilization At Six Months Post-Infection, Analysis Finds

MedPage Today (9/11, Kahn) says patients with COVID-19 treated with “antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months post-infection,” according to a follow-up analysis. Published in The Lancet Infectious Diseases, the analysis shows that “among patients who received molnupiravir 800 mg twice per day plus usual care for 5 days after diagnosis with COVID-19, 8.5% reported persistent symptoms at 6 months compared with 11% who received usual care only.”